- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01283282
Investigation of the Athero-Protective Effects of Clopidogrel (APECS)
15. April 2015 aktualisiert von: Arshed A. Quyyumi, Emory University
Phase 4 Study of Clopidogrel in Patients With Stable Coronary Artery Disease to Determine Effects on Vascular Function, Biomarkers and Endothelial Progrenitor Cells
The investigators would like to investigate whether clopidogrel will help lower the level of harmful markers in patients with coronary artery disease, and at the same time will help increase the cells that are useful in repairing the damaged blood vessels.
The investigators will give half of the patients clopidogrel and the other half a sugar pill, placebo, and check the levels of these markers and helpful cells in each group.
At the same time the investigators will check how well these patient's blood vessels work using ultrasound imaging of the forearm to see how blood vessels relax and tonometry to see how stiff the patient's blood vessels are.
After 6 weeks of drug therapy, the patients will switch to the other drug and these same tests will be performed after an additional 6 weeks of therapy.
The drug taken by the patient will not be known to the patient or the researchers.
The patients will continue on their prescribed medical therapy during the duration of the 12 week study.
Studienübersicht
Status
Abgeschlossen
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Blockages in the blood vessels of the heart are caused by atherosclerosis.
Atherosclerosis is the main cause for chest pain and heart attacks.
Gradual narrowing of the vessels of the heart caused by blockages causes chronic symptoms, such as chest pain.
Those with these findings often have a cardiac catheterization to detect these blockages.
Additionally these patients may have an angioplasty or stent placed to help relieve these symptoms.
With this angioplasty/stent procedure, patients are placed on the drug clopidogrel to help prevent clots from forming and narrowing of the blood vessels.
Clopidogrel is a blood thinner that prevents clots from forming similar to an aspirin, but is more powerful and effective.
Markers, or substances, have been identified that cause worsening of the blockages in the blood vessels of the heart.
Many of these substances have been shown to decrease with the use of clopidogrel.
This occurs separately from clopidogrel's ability to prevent clots.
Endothelial progenitor cells, or EPCs, come mostly from the bone marrow and is helpful in repairing damage to the lining of the blood vessels of the heart.
The EPCs help balance out the damage incurred in the blood vessels from those harmful markers.
Several other drugs commonly used in heart disease have recently been shown to improve EPCs function.
With this in mind, it is important to understand more of clopidogrel's function.
A decrease in markers that cause worsening of the blockages, and an increase in the number of cells that will help repair damaged blood vessels of the heart is important in avoiding future chest pain and heart attacks.
This may be how clopidogrel is currently protecting patients from developing new blockages.
The investigators would like to investigate whether clopidogrel will help lower the level of harmful markers in patients with coronary artery disease, and at the same time will help increase the cells that are useful in repairing the damaged blood vessels.
The investigators will give half of the patients clopidogrel and the other half a sugar pill, placebo, and check the levels of these markers and helpful cells in each group.
At the same time the investigators will check how well these patient's blood vessels work using ultrasound imaging of the forearm to see how blood vessels relax and tonometry to see how stiff the patient's blood vessels are.
After 6 weeks of drug therapy, the patients will switch to the other drug and these same tests will be performed after an additional 6 weeks of therapy.
The drug taken by the patient will not be known to the patient or the researchers.
The patients will continue on their prescribed medical therapy during the duration of the 12 week study.
Studientyp
Interventionell
Einschreibung (Tatsächlich)
48
Phase
- Phase 4
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienorte
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Emory University Hospital
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
21 Jahre bis 80 Jahre (Erwachsene, Älterer Erwachsener)
Akzeptiert gesunde Freiwillige
Nein
Studienberechtigte Geschlechter
Alle
Beschreibung
Inclusion Criteria:
- Male or females without child bearing potential aged 21-80 years
- Known coronary artery disease by angiogram or documented myocardial infarction.
- Able to provide written informed consent
Exclusion Criteria:
- Treated with clopidogrel or ticlodipine in the previous 3 months
- Age < 21 or >80 years
- Premenopausal females with potential for pregnancy
- Allergy to clopidogrel or aspirin
- Initiation or change in dose of any concomitant medical therapy within 2 months before the study
- Uncontrolled hypertension with BP>180 mmHg systolic and >120 mmHg diastolic
- Treated with coumadin therapy
- Intolerance or allergy to statins
- Acute infection in previous 4 weeks
- History of substance abuse
- Uninterpretable PAT test
- Current neoplasm
- Chronic renal failure [creatinine > 2.5 mg/dL] or liver failure (Liver enzymes >2X normal)
- Acute coronary syndrome, heart failure, CVA, coronary intervention within 3 months
- Known aortic stenosis, hypertrophic cardiomyopathy, symptomatic heart failure.
- Inability to give informed consent
- Inability to return to Emory for follow-up
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: Clopidogrel/Placebo
Subjects were randomized to clopidogrel 75 mg daily for 6 weeks.
Then immediately transitioned to a placebo daily for 6 weeks.
|
Clopidogrel 75 mg PO qday for 6 weeks
Andere Namen:
Placebo PO qday for 6 weeks
|
Aktiver Komparator: Placebo/Clopidogrel
Subjects were randomized to a placebo daily for 6 weeks.
Then immediately transitioned to clopidogrel 75 mg daily for 6 weeks.
|
Clopidogrel 75 mg PO qday for 6 weeks
Andere Namen:
Placebo PO qday for 6 weeks
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Flow-mediated Dilation (FMD)
Zeitfenster: Baseline, Week 12
|
Flow-mediated dilation (FMD) collected by an ultrasound and is measured by the percent change in diameter of the brachial artery from baseline to 12 weeks.
|
Baseline, Week 12
|
Nitroglycerin-mediated Vasodilation
Zeitfenster: Baseline, Week 12
|
Nitroglycerin (NTG)-mediated vasodilation was measured after 0.4 mg of NTG was administered sublingually.
Brachial artery images were obtained via ultrasound after three minutes of NTG administration.
Measurements from the twelve frames will be averaged to calculate the percent change in diameter of the brachial artery from baseline to 12 weeks.
|
Baseline, Week 12
|
Endothelial Progenitor Cells (EPCs)
Zeitfenster: Week 12
|
The circulating progenitor-enriched population of cells was measured by the expression of surface antigens using direct flow cytometry for CD34+, CD34+/CD133+, CD34+/ VEGF2R+ and CD34+/CD133+/VEGF2R+
|
Week 12
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Pulse Wave Velocity (PWV)
Zeitfenster: Week 12
|
PWV was measured between the carotid and femoral arteries using the SphygmoCor device.
Pressure waveforms at the carotid and femoral arteries were acquired using EKG gating.
Velocity (distance per time in seconds) was calculated using the foot-to-foot method and the distance between the sites was measured manually.
|
Week 12
|
Oxidative Stress Markers
Zeitfenster: Week 12
|
Oxidative stress was measured by using liquid chromatography to collect plasma cystine, cysteine, gluthione, and oxidized glutathione levels.
|
Week 12
|
Inflammatory Marker High-sensitivity C-reactive Protein (hsCRP)
Zeitfenster: Week 12
|
High-sensitivity C-reactive protein (hsCRP) was measured.
The hsCRP levels were measured by Dade Behring nephelometry.
|
Week 12
|
Inflammatory Marker CD40 Ligand
Zeitfenster: Week 12
|
CD40 ligand levels were measured.
The level of CD40 ligand were measured using the Flurokine MultiAnalyte profiling (MAP) Human Base Kit B.
|
Week 12
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Sponsor
Ermittler
- Hauptermittler: Ziyad Ghazzal, MD, American University of Beirut, Emory University
Publikationen und hilfreiche Links
Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn
1. Januar 2008
Primärer Abschluss (Tatsächlich)
1. Dezember 2010
Studienabschluss (Tatsächlich)
1. Dezember 2010
Studienanmeldedaten
Zuerst eingereicht
24. Januar 2011
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
24. Januar 2011
Zuerst gepostet (Schätzen)
25. Januar 2011
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
1. Mai 2015
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
15. April 2015
Zuletzt verifiziert
1. April 2015
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Herzkrankheiten
- Herz-Kreislauf-Erkrankungen
- Gefäßerkrankungen
- Arteriosklerose
- Arterielle Verschlusskrankheiten
- Koronare Herzkrankheit
- Myokardischämie
- Koronare Krankheit
- Physiologische Wirkungen von Arzneimitteln
- Neurotransmitter-Agenten
- Molekulare Mechanismen der pharmakologischen Wirkung
- Thrombozytenaggregationshemmer
- Purinerge P2Y-Rezeptorantagonisten
- Purinerge P2-Rezeptorantagonisten
- Purinerge Antagonisten
- Purinerge Wirkstoffe
- Clopidogrel
Andere Studien-ID-Nummern
- IRB00005145
- APECS (Andere Kennung: Other)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Clopidogrel
-
Korea University Anam HospitalAbgeschlossen
-
Ospedale San DonatoAbgeschlossen
-
Hospital Central San Luis Potosi, MexicoUnbekanntAkutes Koronar-Syndrom
-
University of North Carolina, Chapel HillAbgeschlossen
-
Deutsches Herzzentrum MuenchenBeendetKoronare HerzkrankheitDeutschland
-
University of PecsHungarian Academy of Sciences; KRKAAbgeschlossenKoronare Herzerkrankung | Perkutane Koronarintervention
-
Ajou University School of MedicineDong-A PharmaceuticalAbgeschlossen
-
Chinese PLA General HospitalUnbekanntGenotypisierung Geführte individualisierte Behandlung von Clopidogrel und Ticagrelor bei ACS (GI-CT)CLOPIDOGREL, SCHLECHTER STOFFWECHSEL von (Störung)China
-
University of PecsAbgeschlossenAkutes Koronar-SyndromUngarn